Sign in →

Test Code PHI11 Prostate Health Index (phi), Serum


Specimen Required


Patient Preparation:

1. Specimens for testing should be drawn prior to prostate manipulations such as digital rectal examination (DRE), prostatic massage, transrectal ultrasound (TRUS), and prostatic biopsy.

2. Specimens should not be collected from patients receiving therapy with high biotin (vitamin B7) doses (ie, >5 mg/day) until at least 8 hours following the last biotin administration.

Collection Container/Tube: Red top

Submission Container/Tube: Plastic vial

Specimen Volume: 1 mL

Collection Instructions: Spin down within 3 hours of draw and separate serum from cells.


Useful For

Aids in distinguishing prostate cancer from benign prostate conditions in men with total prostate-specific antigen (PSA) concentrations in the 4 to 10 ng/mL range and digital rectal examination (DRE) findings that are not suspicious for cancer

Reflex Tests

Test ID Reporting Name Available Separately Always Performed
PHI13 Prostate Health Index (phi) No No

Testing Algorithm

This test begins with the analysis of prostate-specific antigen (PSA). If the PSA is between 2.0 and 10.0 ng/mL, then the reflex test (PHI13) will be performed.

 

If the initial PSA is between 2.0 and 10.0 ng/mL, then free PSA and [-2]ProPSA will be reported.

If the initial PSA is between 4.0 and 10.0 ng/mL, then the percent free PSA and prostate health index (phi) will be calculated and reported.

If the initial PSA is between 2.0 and 4.0 ng/mL, then the percent free PSA and prostate health index (phi) will not be calculated or reported.

Method Name

Immunoenzymatic Assay

Reporting Name

Prostate Health Index (phi), S

Specimen Type

Serum Red

Specimen Minimum Volume

0.75 mL

Specimen Stability Information

Specimen Type Temperature Time
Serum Red Frozen 150 days

Reject Due To

Hemolysis

Mild OK; Gross reject

Lipemia

NA

Icterus

Mild OK; Gross reject

Other

SST Serum reject

Reference Values

Females: Not applicable

 

TOTAL PROSTATE-SPECIFIC ANTIGEN (PSA)

Males:

Age

Reference Range

<40 years

≤2.0 ng/mL

40-49 years

≤2.5 ng/mL

50-59 years

≤3.5 ng/mL

60-69 years

≤4.5 ng/mL

70-79 years

≤6.5 ng/mL

≥80 years

≤7.2 ng/mL

 

PERCENT FREE PSA

Males:

When total PSA is in the range of 4-10 ng/mL

% Free PSA

Probability of Cancer

≤<10%

56%

11-15%

28%

16-20%

20%

21-25%

16%

>25%

8%

 

PROSTATE HEALTH INDEX (phi)

Males:

When total PSA is in the range of 4-10 ng/mL

phi Range

Probability of Cancer

95% Confidence Interval

0-26.9

9.8%

5.2-15.4%

27.0-35.9

16.8%

11.3-22.2%

36.0-54.9

33.3%

26.8-39.9%

≥55.0

50.1%

39.8-61.0%

Day(s) and Time(s) Performed

Monday through Friday; 6 a.m.-12 a.m.

Saturday; 6:30 a.m.-5 p.m.

Analytic Time

1 day

Performing Laboratory

Mayo Medical Laboratories in Rochester

Test Classification

This test has been cleared or approved by the U.S. Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.

CPT Code Information

84153

LOINC Code Information

Test ID Test Order Name Order LOINC Value
PHI11 Prostate Health Index (phi), S In Process

 

Result ID Test Result Name Result LOINC Value
PHI12 Prostate Specific Antigen, S 2857-1

Forms

If not ordering electronically, complete, print, and send the following form with the specimen:

Prostate Health Index (phi), Serum Test Request Form (T792) (http://www.mayomedicallaboratories.com/it-mmfiles/PHI-request-form.pdf)